Scientific validation of OGM expands potential market applications to 40+ repeat expansion disorders, strengthening Bionano's position in genetic testing marketplace. This publication represents significant scientific validation for Bionano's core technology platform in a specific clinical application area with substantial market potential. Repeat expansions are linked to approximately 40 genetic disorders, creating a distinct market segment where OGM technology appears to offer technical advantages. The demonstrated ability to provide a single, comprehensive assay across multiple genetic loci could translate to operational efficiencies in clinical genetics laboratories. While specific cost comparisons aren't detailed in the article, the potential for reduced turnaround time and lower costs through workflow consolidation represents a compelling value proposition in the resource-constrained diagnostics environment.